Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

PURPOSE: To evaluate the association between neutrophil-to-lymphocyte ratio (NLR) and efficacy of avelumab plus axitinib or sunitinib. EXPERIMENTAL DESIGN: Adult patients with untreated advanced renal cell carcinoma (RCC) with a clear-cell component, ≥1 measurable lesions, Eastern Cooperative Oncolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilen, Mehmet A., Rini, Brian I., Voss, Martin H., Larkin, James, Haanen, John B.A.G., Albiges, Laurence, Pagliaro, Lance C., Voog, Eric G., Lam, Elaine T., Kislov, Nikolay, McGregor, Bradley A., Lalani, Aly-Khan A., Huang, Bo, di Pietro, Alessandra, Krulewicz, Stan, Robbins, Paul B., Choueiri, Toni K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377757/
https://www.ncbi.nlm.nih.gov/pubmed/34789480
http://dx.doi.org/10.1158/1078-0432.CCR-21-1688

Ejemplares similares

Ejemplares similares